Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 8Phase 1/2 3Phase EARLY_PHASE1 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 1Cytokine Release Syndrome 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
33 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06703216 2025-06-15

PACER

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Not yet recruiting
24 enrolled
Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma

NCT03430011 2024-05-24

EVOLVE

Juno Therapeutics, a Subsidiary of Celgene

Phase 1/2 Completed
165 enrolled 38 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡